What was recalled
This page synthesizes the therapeutic framework around pancreatic enzyme replacement therapy for canine and feline exocrine pancreatic insufficiency (EPI). The page does not address pet food fortification directly — the framework here is veterinary therapeutic and the relevant context for EPI-diagnosed pets is supplementation, not kibble-included enzyme content. EPI prevalence in dogs is approximately 0.5-1% across breeds with substantial breed concentration: German Shepherds account for approximately 50% of canine EPI cases despite representing a smaller percentage of the overall dog population, with Rough Collies, Eurasiers, English Setters, Cavalier King Charles Spaniels, and Chow Chows also overrepresented. Feline EPI prevalence is estimated at 0.05-0.1% and is more commonly secondary to chronic pancreatitis than primary acinar atrophy.
The standard treatment is pancrelipase (also called pancreatin), a porcine pancreatic enzyme extract containing the three primary digestive enzymes: lipase (~75% of activity by weight; degrades triglycerides into monoglycerides and free fatty acids), protease (~15% of activity; degrades proteins into peptides and amino acids), and amylase (~10% of activity; degrades starches into oligosaccharides and disaccharides). Commercial pancrelipase products are derived from porcine pancreatic glands collected at slaughter and extracted through defined pharmaceutical processing. Activity is standardized in USP units (USP-defined activity) or international units (IU), with typical product strength being 71,400 USP lipase units per teaspoon of powder for veterinary products.
The formulation framework includes two main approaches: (i) raw powder formulations (Pancrezyme, Viokase, Epiklin) are designed to be mixed with food immediately before feeding, with the enzyme acting on the food in the gastric environment and continuing through the small intestine; raw powder formulations typically require larger dose volumes (1 teaspoon per cup of food typical) and can produce oral mucosal irritation in some dogs requiring careful handling; (ii) enteric-coated capsules (Creon and similar human products used off-label in veterinary medicine) provide acid-protected enzyme delivery to the small intestine, with reduced gastric inactivation but reduced gastric-phase digestion contribution; enteric-coated products are smaller in dose volume but typically more expensive per therapeutic dose. The framework choice depends on the individual pet response, dosing convenience, gastric acidity management (some EPI dogs benefit from concurrent gastric acid suppression with H2 blockers or proton pump inhibitors to reduce raw pancrelipase inactivation), and dietary management considerations.
Why it was recalled
The structural concerns have three layers. Layer one — pet food enzyme fortification does not address EPI therapeutic needs: EPI requires therapeutic enzyme dosing far above what any pet food can deliver. Therapeutic pancrelipase dosing in dogs is typically 1 teaspoon (about 4-5 grams) of raw powder per cup of food at every meal, delivering ~71,400 USP lipase units per teaspoon. Pet food fortification at <0.1% of diet at standard activity delivers a small fraction of this. Pet owners with EPI-diagnosed dogs must use veterinary-tier pancrelipase supplementation. Marketing that suggests enzyme-fortified kibble can address EPI is misleading and clinically inadequate.
Layer two — gastric acid inactivation of raw pancrelipase is a known clinical challenge: raw pancrelipase enzymes are partially inactivated by gastric acid (pH 1-3 in normal canine stomach). The clinical workaround includes: (i) concurrent gastric acid suppression with H2 blockers (famotidine, ranitidine) or proton pump inhibitors (omeprazole, esomeprazole) to raise gastric pH and reduce enzyme inactivation; (ii) enteric-coated capsule formulations that resist gastric acid degradation; (iii) pre-incubation of pancrelipase with food at body temperature for 15-30 minutes before feeding, allowing enzymatic digestion to begin in the bowl before gastric exposure (controversial in clinical practice with mixed evidence for benefit). The framework choice depends on individual pet response and veterinary clinical management.
Layer three — vitamin B12 (cobalamin) deficiency is a common EPI complication requiring concurrent management: approximately 80% of EPI dogs and a majority of EPI cats develop concurrent vitamin B12 deficiency due to: (i) reduced intrinsic factor production from pancreatic insufficiency (cats only; canine intrinsic factor is gastric); (ii) small intestinal bacterial overgrowth (SIBO) due to disrupted pancreatic antimicrobial peptide secretion and bicarbonate buffer reduction; (iii) ileal cobalamin receptor downregulation from chronic inflammation. The framework gap is that EPI management requires concurrent cobalamin supplementation (typically 250-1000 mcg parenteral cyanocobalamin weekly initially, transitioning to less frequent maintenance) alongside pancrelipase, with the cobalamin management often overlooked in pet food fortification discussions.
Health risks for your pet
Pancrelipase is generally well-tolerated when used appropriately for EPI management. Common adverse effects include: (i) oral mucosal irritation in dogs with raw powder formulations (particularly when administered without adequate food mixing); the irritation can be minimized by thorough mixing with food, brief pre-incubation, and adequate food volume; (ii) diarrhea persistence in some EPI dogs despite pancrelipase supplementation, often due to concurrent SIBO requiring antibiotic management (tylosin or metronidazole); (iii) cost burden for lifelong supplementation (typical monthly cost $50-200 depending on pet size and formulation); (iv) allergic sensitization rarely reported in pet owners handling raw pancrelipase powder over extended periods (porcine protein exposure); (v) hyperuricosuria in rare cases from purine load in pancreatic extract (clinical relevance minimal for most pets).
The clinical outcome framework: with adequate pancrelipase supplementation, gastric acid management, cobalamin supplementation, and dietary management (typically low-residue, moderate-fat diet; some EPI dogs benefit from highly digestible therapeutic GI diets), most EPI dogs achieve and maintain near-normal body weight and clinical signs resolution within 4-12 weeks of treatment initiation. Long-term prognosis is excellent for dogs with primary pancreatic acinar atrophy; prognosis for EPI secondary to chronic pancreatitis or neoplasia depends on the underlying disease management. Approximately 5-10% of EPI dogs do not respond adequately to standard pancrelipase therapy and require additional diagnostic workup for concurrent disease (small intestinal bacterial overgrowth, inflammatory bowel disease, lymphoma).
What to do if you bought affected product
Pet owners with EPI-diagnosed dogs or cats should follow these practical approaches: (1) use veterinary-prescribed pancrelipase, not pet food fortification — therapeutic enzyme dosing for EPI requires veterinary-tier supplementation (Pancrezyme, Viokase, Epiklin, PancreVed, or human enteric-coated products like Creon used off-label); pet food enzyme fortification is several orders of magnitude below therapeutic dose; (2) follow your veterinarian's specific dosing protocol — typical canine starting dose is 1 teaspoon of raw powder per cup of food at every meal, with adjustment based on clinical response (weight gain, stool consistency normalization, appetite normalization); feline dosing scales proportionally; (3) request concurrent vitamin B12 (cobalamin) assessment and supplementation — approximately 80% of EPI dogs and majority of EPI cats develop cobalamin deficiency; serum cobalamin testing at diagnosis with parenteral cyanocobalamin supplementation (typically 250-1000 mcg weekly initially) is standard clinical practice; (4) consider concurrent gastric acid suppression — H2 blockers (famotidine) or proton pump inhibitors (omeprazole) reduce gastric inactivation of raw pancrelipase and improve treatment efficacy in some dogs; coordinate with your veterinarian; (5) monitor for diarrhea persistence despite adequate pancrelipase — persistent diarrhea may indicate concurrent SIBO requiring antibiotic management (tylosin 25 mg/kg twice daily for 4-6 weeks is a common veterinary protocol); (6) use a highly digestible, low-residue dietary base — therapeutic GI diets (Hill's i/d, Royal Canin Gastrointestinal, Purina EN, Iams ProActive Health Sensitive) often improve EPI clinical signs; some EPI dogs respond better to fresh-frozen or gently-cooked diets than to extruded kibble; (7) handle raw pancrelipase powder carefully — mix thoroughly with food, avoid prolonged skin contact, and follow veterinary instructions for any pre-incubation protocol; oral mucosal irritation in dogs can be minimized by thorough mixing; (8) monitor clinical response with regular veterinary follow-up — weight gain trajectory, stool consistency normalization, appetite normalization, and cobalamin status reassessment are the key clinical endpoints; most EPI dogs stabilize within 4-12 weeks with appropriate treatment.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not score for EPI therapeutic adequacy of pet food per our published methodology, since EPI management is a veterinary therapeutic context requiring prescription supplementation outside the scope of consumer-facing kibble selection. Pet food brands marketing enzyme fortification as adequate for EPI management are clinically misleading; veterinary-tier pancrelipase supplementation is essential. Related framework coverage is across our best dog food for EPI guide (which specifically addresses dietary base selection for EPI-diagnosed dogs), best dog food for pancreatitis guide, and kibble-glaze enzyme processing controversy. For now, our recommendation: EPI-diagnosed pets require veterinary-prescribed pancrelipase supplementation, concurrent cobalamin supplementation, gastric acid management if indicated, and highly digestible therapeutic dietary base; pet food enzyme fortification is inadequate for EPI management and should not be relied upon.